The prevalence of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections is increasing globally and in Singapore. Skin and soft tissue infections (SSTIs) are the most common manifestations, ranging from common furuncles to the rare but life-threatening necrotizing fasciitis. Surgical drainage and debridement where feasible are the mainstay of therapy, whereas MRSA-active antibiotics are essential when surgery is not possible or as adjunctive therapy for severe and/or complicated SSTIs. In itself, the continued inexorable rise in CA-MRSA rates poses difficult challenges for primary healthcare and hospital infection control. Innovative approaches are required to mitigate its impact in both the community and hospital settings.
NaimiTSLeDellKHComo-SabettiKBorchardtSMBoxrudDJEtienneJ. Comparison of community- and healthcare-associated methicillin-resistant Staphylococcus aureus infection. JAMA2003;290:2976–84.
2.
StewartGTHoltRJ. Evolutio of natural resistance to the newer penicillins. Br Med J. 1963;5326:308–11.
3.
UtsuiYYokotaT. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1985;28:397–403.
4.
OkumaKIwakawaKTurnidgeJDGrubbWBBellJMO'BrienFG. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol. 2002;40:4289–94.
5.
International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC). Classification of staphylococcal cassette chromosome mec (SCCmec): Guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother. 2009;53:4961–7.
6.
EnrightMCRobinsonDARandleGFeilEJGrundmannHSprattBG. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA. 2002;99:7687–92.
7.
KatayamaYZhangHZHongDChambersHF. Jumping the barrier to β-lactam resistance in Staphylococcus aureus. J Bacteriol. 2003;185:5465–72.
8.
KatayamaYRobinsonDAEnrightMCChambersHF. Genetic background affects stability of mecA in Staphylococcus aureus. J Clin Microbiol. 2005;43:2380–3.
UdoEEPearmanJWGrubbWB. Genetic analysis of community isolates of methicillin-resistant Staphylococcus aureus in Western Australia. J Hosp Infect. 1993;25:97–108.
11.
HeroldBCImmergluckLCMarananMCLauderdaleDSGaskinREBoyle-VavraS. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279:593–8.
12.
SalgadoCDFarrBMCalfeeDP. Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin Infect Dis. 2003;36:131–9.
BabaTTakeuchiFKurodaMYuzawaHAokiKOguchiA. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet2002;359:1819–27.
15.
EnderMMcCallumNAdhikariRBachiB Berger. Fitness cost of SCCmec and methicillin resistance levels in Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:2295–7.
16.
LeeSMEnderMAdhikariRSmithJMBerger-BachiBCookGM. Fitness cost of staphylococcal cassette chromosome mec in methicillin-resistant Staphylococcus aureus by way of continuous culture. Antimicrob Agents Chemother. 2007;51:1497–9.
17.
HsuLYKohTHSinghKKangMLKurupATanBH. Dissemination of multisusceptible methicillin-resistant Staphylococcus aureus in Singapore. J Clin Microbiol. 2005;43:2923–5.
18.
DonnioPPreneyYLGautier-LerestifALAvrilJLLafforgueN. Changes in the staphylococcal cassette chromosome type and antibiotic resistance profile in methicillin-resistant Staphylococcus aureus isolates from a French hospital over an 11 year period. J Antimicrob Chemother. 2004;53:808–13.
19.
ChenCJHsuehPRSuLHChiuCHLinTYHuangYC. Change in the molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream infections in Taiwan. Diagn Microbiol Infect Dis. 2009;65:199–201.
20.
GonzalezBERuedaAMShelburneSA3rdMusherDMHamillRJHultenKG. Community-associated strains of methicillin-resistant Staphylococcus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol. 2006;27:1051–1056.
LinaGPiemontYGodail-GamotFBesMPeterMOGauduchonV. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128–32.
23.
IssartelBTristanALechevallierSBruyereFLinaGGarinB. Frequent carriage of Panton-Valentine leucocidin genes by Staphylococcus aureus isolates from surgically drained abscesses. J Clin Microbiol. 2005;43:3203–7.
24.
O'BrienFGLimTTChongFNCoombsGWEnrightMCRobinsonDA. Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J Clin Microbiol2004;42:3185–3190.
25.
RossneyASShoreACMorganPMFitzgibbonMMO'ConnellBColemanDC. The emergence and importation of diverse genotypes of methicillin-resistant Staphylococcus aureus (MRSA) harboring the Panton-Valentine leukocidin gene (pvl) reveal that pvl is a poor marker for community-acquired MRSA strains in Ireland. J Clin Microbiol2007;45:2554–63.
26.
DeurenbergRHVinkCKalenicSFriedrichAWBruggemanAStobberinghEE. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin Microb Infect. 2007;13:222–35.
HsuLYKohYLChlebickaNLTanTYKrishnanPLinRT. Establishment of ST30 as the predominant clonal type among community-associated methicillin-resistant Staphylococcus aureus isolates in Singapore. J Clin Microbiol. 2006;44:1090–3.
29.
WijayaLHsuLYKurupA. Community-associated methicillin-resistant Staphylococcus aureus: Overview and local situation. Ann Acad Med Singapore. 2006; 35:479–86.
30.
HoPLChuangSKChoiYFLeeRALitACNgTK. Community-associated methicillin-resistant and methicillin-sensitive Staphylococcus aureus: Skin and soft tissue infections in Hong Kong. Diagn Microbiol Infect Dis. 2008;61:245–50.
31.
BartelsMDKristoffersenKBoyeKWesthH. Rise and subsequent decline of community-associated methicillin-resistant Staphylococcus aureus ST30-IVc in Copenhagen, Denmark through an effective search and destroy policy. Clin Microbiol Infect. 2010;16:78–83.
32.
MillerLGPerdreau-RemingtonFRiegGMehdiSPerlrothJBayerAS. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med. 2005;352:1445–53.
33.
LeeYTLinJCWangNCPengMYChangFY. Necrotizing fasciitis in a medical center in northern Taiwan: Emergence of methicillin-resistant Staphylococcus aureus in the community. J Microbiol Immunol Infect. 2007;40:335–41.
34.
Martinez-AguilarGAvalos-MishaanAHultenKHammermanWMasonEOJr.KaplanSL. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J. 2004;23:701–6.
35.
PannarajPSHultenKGGonzalezBEMasonEOJrKaplanSL. Infective Pyomyositis and Myositis in Children in the Era of Community-Acquired, Methicillin-Resistant Staphylococcus aureus Infection. Clin Infect Dis. 2006;43:953–60.
36.
FrancisJSDohertyMCLopatinUJohnstonCPSinhaGRossT. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40:100–7.
37.
Centers for Disease Control and Prevention. From the Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus–Minnesota and North Dakota, 1997–1999. JAMA. 1999;282:1123–5.
FridkinSKHagemanJCMorrisonMSanzaLTComo-SabettiKJerniganJA. Methicillin-Resistant Staphylococcus aureus Disease in Three Communities. N Engl J Med. 2005;352:1463–44.
40.
FrazeeBWLynnJCharleboisEDLambertLLoweryDPerdreau-RemingtonF. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med. 2005;45:311–20.
41.
MoranGJKrishnadasanAGorwitzRJFosheimGEMcDougalLKCareyRB. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666–74.
42.
BaggettHHennessyTLemanRHamlinCBrudenDReasonoverA. An outbreak of community-onset methicillin-resistant Staphylococcus aureus skin infections in southwestern Alaska. Infect Control Hosp Epidemiol. 2003;24:397–402.
43.
BratuSEramoAKopecRCoughlinEGhitanMYostR. Community-associated methicillin-resistant Staphylococcus aureus in hospital nursery and maternity units. Emerg Infect Dis. 2005;11:808–13.
44.
GouldIMGirvanEKBrowningRAMacKenzieFMEdwardsGF. Report of a hospital neonatal unit outbreak of community-associated methicillin-resistant Staphylococcus aureus. Epidemiol Infect. 2009;137:1242–8.
45.
Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections in correctional facilities—Georgia, California, and Texas, 2001–2003. MMWR Morb Mortal Wkly Rep. 2003;52:992–6.
46.
Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus skin infections among tattoo recipients–Ohio, Kentucky, and Vermont, 2004–2005. MMWR Morb Mortal Wkly Rep. 2006;55:677–9.
47.
ZindermanCConnerBMalakootiMLaMarJArmstrongABohnkerB. Community-acquired methicillin-resistant Staphylococcus aureus among military recruits. Emerg Infect Dis. 2004;10:941–4.
48.
Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants –Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000–2003. MMWR Morb Mortal Wkly Rep. 2003;52:793–5.
49.
BegierEFrenetteKBarrettNLMsharPPetitSBoxrudDJ. A high morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis. 2004;39:1446–53.
50.
ArchibaldLShapiroJPassARandKSouthwickF. Methicillin-resistant Staphylococcus aureus infection in a college football team: Risk factors outside the locker room and playing field. Infect Control Hosp Epidemiol. 2008;29:450–3.
51.
KazakovaSHagemanJMatavaMSrinivasanAPhelanLGarfinkelB. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med. 2005;352:468–75.
52.
LindenmayerJMSchoenfeldSO'GradyRCarneyJK. Methicillin-resistant Staphylococcus aureus in a high school wrestling team and the surrounding community. Arch Intern Med. 1998;158:895–9.
RuheJJSmithNBradsherRWMenonA. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: Impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007;44:777–84.
55.
MillerLGQuanCShayAMostafaieKBharadwaKTanN. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis. 2007;44:483–92.
56.
LeeMCRiosAMAtenMFMejiasACavuotiDMcCrackenGHJr.. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2004;23:123–7.
57.
PrunierALMalbrunyBTandeDPicardBLeclercqR. Clinical isolates of Staphylococcus aureus with ribosomal mutations conferring resistance to macrolides. Antimicrob Agents Chemother. 2002;46:3054–6.
58.
SteinkrausGWhiteRFriedrichL. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother. 2007;60:788–94.
59.
RobertJBismuthRJarlierV. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: A 20 year study in a large French teaching hospital, 1993–2002. J Antimicrob Chemother. 2006;57:506–10.
60.
SorianoAMarcoFMartinezJAPisosEAlmelaMDimovaVP. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193–200.
61.
HidayatLKHsuDIQuistRShrinerKAWong-BeringerA. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med2006;166:2138–44.
62.
WeigeltJItaniKStevensDLauWDrydenMKnirschC. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260–6.
63.
ItaniKMDrydenMSBhattacharyyaHKunkelMJBaruchAMWeigeltJA. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010. 199;804–16.
64.
ArbeitRDMakiDTallyFPCampanaroEEisensteinBI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673–81.
65.
EllisGrosse EJ, Babinchak T, Dartois N, Rose G, Lo E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: Results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41Suppl 5:S341–53.
66.
NoelGJStraussRSAmslerKHeepMPypstraRSolomkinJS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother2008;52:37–44.
67.
ParishDScheinfeldN. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs2008;9:201–09.
68.
ChambersHF. The changing epidemiology of Staphylococcus aureus?Emerg Infect Dis. 2001;7:178–82.
